Amarin Corporation PLC (NASDAQ:AMRN) — Market Cap & Net Worth
Market Cap & Net Worth: Amarin Corporation PLC (AMRN)
Amarin Corporation PLC (NASDAQ:AMRN) has a market capitalization of $290.84 Million ($290.84 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15074 globally and #3558 in its home market, demonstrating a -3.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amarin Corporation PLC's stock price $13.87 by its total outstanding shares 20969109 (20.97 Million). Also see balance sheet size of Amarin Corporation PLC for a full breakdown of the balance sheet.
Amarin Corporation PLC Market Cap History: 2015 to 2026
Amarin Corporation PLC's market capitalization history from 2015 to 2026. Data shows growth from $39.63 Million to $290.84 Million (19.51% CAGR). Also see AMRN cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Amarin Corporation PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #410 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1462 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #212 of 263 |
Weight: Amarin Corporation PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amarin Corporation PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amarin Corporation PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Amarin Corporation PLC stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.37x
Amarin Corporation PLC's market cap is 1.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $64.58 Million | $130.08 Million | -$86.35 Million | 0.50x | N/A |
| 2017 | $84.09 Million | $181.10 Million | -$67.86 Million | 0.46x | N/A |
| 2018 | $285.39 Million | $229.21 Million | -$116.44 Million | 1.25x | N/A |
| 2019 | $449.58 Million | $429.75 Million | -$22.64 Million | 1.05x | N/A |
| 2020 | $102.54 Million | $614.06 Million | -$18.00 Million | 0.17x | N/A |
| 2021 | $70.67 Million | $583.19 Million | $7.73 Million | 0.12x | 9.14x |
| 2022 | $25.37 Million | $369.19 Million | -$105.80 Million | 0.07x | N/A |
| 2023 | $18.24 Million | $306.91 Million | -$59.11 Million | 0.06x | N/A |
| 2024 | $10.17 Million | $228.61 Million | -$82.18 Million | 0.04x | N/A |
| 2025 | $292.62 Million | $213.65 Million | -$38.80 Million | 1.37x | N/A |
Competitor Companies of AMRN by Market Capitalization
Companies near Amarin Corporation PLC in the global market cap rankings as of September 18, 2026. Review AMRN intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Amarin Corporation PLC by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #44 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.44 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.22 |
| #44 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $264.02 |
Amarin Corporation PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Amarin Corporation PLC's market cap moved from $39.63 Million to $ 290.84 Million, with a yearly change of 19.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $290.84 Million | -0.61% |
| 2025 | $292.62 Million | +2777.32% |
| 2024 | $10.17 Million | -44.25% |
| 2023 | $18.24 Million | -28.10% |
| 2022 | $25.37 Million | -64.09% |
| 2021 | $70.67 Million | -31.08% |
| 2020 | $102.54 Million | -77.19% |
| 2019 | $449.58 Million | +57.53% |
| 2018 | $285.39 Million | +239.40% |
| 2017 | $84.09 Million | +30.19% |
| 2016 | $64.58 Million | +62.96% |
| 2015 | $39.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Amarin Corporation PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $290.84 Million USD |
| MoneyControl | $290.84 Million USD |
| MarketWatch | $290.84 Million USD |
| marketcap.company | $290.84 Million USD |
| Reuters | $290.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more